Overall, our results support the potential use of Napabucasin as an efficacious anti-tumor therapeutic agent with a probability of better outcome in high-MUC1 tumor sub-populations, singly or in combination with other therapeutic agents. This evidence concerns the gene MUC1 and neoplasm.